Study shows how an opportunistic microbe kills cancer cells

June 19, 2017
Electron microscopic image of a single human lymphocyte. Credit: Dr. Triche National Cancer Institute

New study results show for the first time how dying cells ensure that they will be replaced, and suggests an ingenious, related new approach to shrinking cancerous tumors. A research team from Rush University Medical Center will publish a new paper this week in the journal Developmental Cell that describes two groundbreaking discoveries.

"I believe this discovery is going to have important ramifications on cancer biology and , and on the treatment of other diseases such as ," says Sasha Shafikhani, PhD, associate professor of Hematology, Oncology and Cell Therapy at Rush Medical College, who headed up the study.

The team made its two-pronged discovery while investigating how an opportunistic microbe kills cancer cells. For years, Shafikhani's lab has been studying Pseudomonas aeruginosa, a bacterium that can be lethal, but only to people who are already wounded or sick. This pathogenic bacterium secretes several toxins that allow it to cause infection. One such toxins, ExoT, inhibits cell division and can severely impede wound healing, but it's also known to kill cancer cells.

The researchers were trying to figure out ExoT's lethal mechanisms against cancer when they unlocked, almost by accident, a mystery researchers have been trying to solve for years, Shafikhani says. For at least 20 years, medical researchers have wondered how cells, before they die in the normal process of , manage to alert their neighbors of the need to replace them and compensate for their demise, so to ensure the organism's survival. While shining a light on the lethal habits of Pseudomonas aeruginosa, Shafikhani's team discovered what actually happens in that "compensatory proliferation signaling" (CPS) process.

For the first time, the investigators saw—and have shown in amazing videos they produced—that during CPS, dying cells release "microvesicles" containing the CrkI protein, which travel to neighboring cells and cause them, upon contact, to create new cells to replace the ones that are dying.

Apoptosis is part of life. "In the course of normal tissue turnover in humans, about one million cells die every second, through a highly-regulated process of apoptotic programmed cell death (PCD)," the new paper states. Apoptosis is not the only type of cell death, and not all cells dying of apoptosis are capable of CPS.

Not only that, but Shafikhani and his colleagues have demonstrated that if they knocked out the CrkI protein during CPS, either genetically or with the ExoT toxin, they could stop cell compensatory proliferation cold. That's a trick P. aeruginosa uses to take advantage of damaged tissues, but it has exciting possibilities for disease treatment as well.

Apoptosis is of particular interest to cancer researchers because majority of the current cancer drugs kill cancer cells by apoptosis.

However, CPS can dog apoptosis in cancer treatment. Yes, treated cancer cells can be induced to die, but before they do, they call on nearby cancer cells to replace them, so the drug loses its effectiveness and the tumor persists. But if the communication between the dying cancer cells and neighboring cancer cells is blocked, Shafikhani says, the hope is that the treated cancer cells would not be replaced when they die, and hopefully the tumor would disappear.

"If it's possible to uncouple CPS from apoptosis, we can develop new drugs that would improve the effectiveness of treatments already in use," Shafikhani says.

In , the CPS process and communication would need to be interrupted to prevent the development of new ; but in other conditions, the CPS process could be enhanced to accelerate the healing process. One of the possible long-term benefits of the discoveries set out in the new Developmental Cell article could be to use of these vesicles to encourage cell proliferation—in diabetic wounds where healing is not going well because are dysfunctional and have reduced ability to regenerate, for example, Shafikhani says.

Explore further: Protein that promotes 'cell-suicide' could revolutionise eye cancer treatment

Related Stories

Protein that promotes 'cell-suicide' could revolutionise eye cancer treatment

December 6, 2016
New research from the University of Liverpool has identified the role of a specific protein in the human body that can help prevent the survival and spread of eye cancer, by initiating cancer 'cell-suicide'.

Researchers find link between common enzyme and cancer prevention

January 24, 2017
A common enzyme found in mammals that kills damaged cells before they become cancerous is being hailed as an important breakthrough in understanding the treatment of the disease.

Researchers reveal how a new class of drugs kills cancer cells

May 20, 2016
A team of Walter and Eliza Hall Institute researchers has worked out how a new class of anti-cancer drugs kills cancer cells, a finding that helps explain how cancer cells may become resistant to treatment.

New drug combination shows promise for resistant leukaemia

May 18, 2016
Patients with acute myeloid leukaemia (AML) can look forward to the development of new therapies following the discovery by Walter and Eliza Hall Institute researchers of a new way to kill cells that are dangerously multiplying.

Researchers discover molecular approach to promote cancer cell death

May 21, 2015
Lung cancer researchers at Winship Cancer Institute of Emory University have discovered a novel strategy to exploit apoptosis, a form of programmed cell death, for the treatment of lung cancer. The protein Bcl-2 is a known ...

Recommended for you

New strategy for unleashing cancer-fighting power of p53 gene

December 13, 2017
Tumor protein p53 is one of the most critical determinants of the fate of cancer cells, as it can determine whether a cell lives or dies in response to stress. In a new study published today in the journal Nature Communications, ...

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.